tiotropium bromide/olodaterol (STIOLTO RESPIMAT)

Diagnosis Considered for Coverage:

• Chronic Obstructive Pulmonary Disease (COPD)

Coverage Criteria:

For diagnosis listed above:

 Inadequate response or intolerable side effect with Anoro Ellipta (longacting beta-agonist (LABA) vilanterol with long-acting antimuscarinic antagonist (LAMA) umeclidinium)

Coverage Duration: one year

Effective Date: 11/29/2023